n-3 PUFA may reduce markers of kidney disease in T2DM

February 8, 2013
n-3 PUFA may reduce markers of kidney disease in T2DM
In patients with type 2 diabetes and evidence of kidney injury, supplementation with n-3 long-chain polyunsaturated fatty acids does not reduce urine albumin excretion but is associated with a reduction in certain markers of kidney injury, according to research published online Dec. 28 in Diabetes Care.

(HealthDay)—In patients with type 2 diabetes and evidence of kidney injury, supplementation with n-3 long-chain polyunsaturated fatty acids (PUFA) does not reduce urine albumin excretion but is associated with a reduction in certain markers of kidney injury, according to research published online Dec. 28 in Diabetes Care.

To examine the effect of n-3 PUFA supplementation on urine albumin excretion and markers of kidney injury, Edgar R. Miller III, M.D., Ph.D., of the Johns Hopkins School of Medicine in Baltimore, and colleagues conducted a randomized, placebo-controlled, two-period crossover trial involving 29 participants with type 2 diabetes and evidence of kidney disease who were given 4 g/day of n-3 PUFA supplements for six weeks.

The researchers found that n-3 PUFA supplementation resulted in non-significant reductions in urine albumin excretion compared with placebo, and correlated with significant reductions in urine neutrophil gelatinase-associated lipocalin (NGAL) excretion. There was no significant effect for n-3 PUFA on of or estimated . In the subgroup of participants taking medications that block the renin-angiotensin-aldosterone system, significant decreases were observed in 24-hour urinary albumin excretion, NGAL, liver fatty acid-binding protein, and N-acetyl β-D-glucosaminidase.

"n-3 PUFA failed to reduce the primary outcome of urine albumin excretion," the authors write. "However, there was a consistent trend of benefit for all urine biomarkers and a significant reduction in NGAL."

Lovaza (n-3 PUFA) and placebo used in the study were provided by GlaxoSmithKline.

Explore further: Fatty acids don't reduce atrial fibrillation recurrence

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Fatty acids don't reduce atrial fibrillation recurrence

December 21, 2012

(HealthDay)—Polyunsaturated fatty acids (n-3 PUFA) do not reduce the recurrence of atrial fibrillation (AF), according to a study published online Dec. 19 in the Journal of the American College of Cardiology.

Warning signs predict kidney injury after surgery

August 12, 2011

Acute kidney injury (AKI) is a common – but preventable -- complication after surgery that can lead to other complications or even death. The use and development of biomarkers will help physicians diagnose and treat ...

Recommended for you

New theory on how insulin resistance, metabolic disease begin

September 26, 2016

Does eating too much sugar cause type 2 diabetes? The answer may not be simple, but a study published Sept. 26 in the Journal of Clinical Investigation adds to growing research linking excessive sugar consumption—specifically ...

Unique molecular atlas of pancreas produced

September 23, 2016

Researchers at Karolinska Institutet have managed to produce the first molecular map of the genes that are active in the various cells of the human pancreas. They have also revealed differences in genetic activity between ...

Can long naps cause diabetes?

September 14, 2016

A study presented at a scientific congress Thursday reported a link between long naps and a higher risk of diabetes, though it couldn't say if daytime sleeping was a symptom or a cause.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.